Patents by Inventor Hailong Jiao

Hailong Jiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nitrobenzyl derivatives of anti-cancer agents
    Patent number: 11535585
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: December 27, 2022
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS
    Publication number: 20210017120
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 21, 2021
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Nitrobenzyl derivatives of anti-cancer agents
    Patent number: 10829437
    Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: November 10, 2020
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • DNA alkylating agents
    Patent number: 10766914
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: September 8, 2020
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Aziridine containing DNA alkylating agents
    Patent number: 10668047
    Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: June 2, 2020
    Assignee: Molecular Templates, Inc.
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • AZIRIDINE CONTAINING DNA ALKYLATING AGENTS
    Publication number: 20200085786
    Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 19, 2020
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
    Patent number: 10409869
    Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 10, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • DNA alkylating agents
    Patent number: 10364261
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: July 30, 2019
    Assignee: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • DNA ALKYLATING AGENTS
    Publication number: 20190225633
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 25, 2019
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • (R)- AND (S)-1-(3-(3-N,N-DIMETHYLAMINOCARBONYL)PHENOXYL-4-NITROPHENYL)-1-ETHYL-N,N'-BIS (ETHYLENE)PHOSPHORAMIDATE, COMPOSITIONS AND METHODS FOR THEIR USE AND PREPARATION
    Publication number: 20180258116
    Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N?-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: November 15, 2016
    Publication date: September 13, 2018
    Applicant: OBI Pharma, Inc.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • AZIRIDINE CONTAINING DNA ALKYLATING AGENTS
    Publication number: 20180169064
    Abstract: Provided herein are compounds of formula (I)-(VI), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 21, 2018
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS
    Publication number: 20180086693
    Abstract: Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 29, 2018
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • DNA ALKYLATING AGENTS
    Publication number: 20180044360
    Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 15, 2018
    Applicant: OBI PHARMA, INC.
    Inventors: Jian-Xin Duan, Yeyu Cao, Xiaohong Cai, Hailong Jiao, Jing Yuan Ma, Mark Matteucci
  • Phosphoramidate alkylator prodrugs
    Patent number: 9226932
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: January 5, 2016
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Phosphoramidate Alkylator Prodrugs
    Publication number: 20140170240
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Phosphoramidate alkylator prodrugs
    Patent number: 8664204
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 4, 2014
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS
    Publication number: 20130303778
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 14, 2013
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Camptothecin derivatives
    Patent number: 8575188
    Abstract: Various 14-nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. 14-Nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: November 5, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Xiaohong Cai, Jian-Xin Duan, Mark Matteucci, Yeyu Cao, Hailong Jiao
  • Phosphoramidate alkylator prodrugs
    Patent number: 8507464
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 13, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Hypoxia activated drugs of nitrogen mustard alkylators
    Patent number: 8309554
    Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: November 13, 2012
    Assignee: Threshold Pharmaceuticals
    Inventors: Jason Lewis, Mark Matteucci, Tao Chen, Hailong Jiao